NEW YORK (GenomeWeb News) – Epigenomics today said that it has established a Level 1 American Depositary Receipt program enabling the firm to trade publicly in the US.

The Berlin, Germany-based molecular diagnostics firm said that its ADRs are US dollar-negotiable certificates that represent ordinary shares of the company at a ratio of five ordinary shares to one Epigenomics ADR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.